Drug Profile
Cannabidiol dry powder inhalation- MannKind Corporation/Receptor Life Sciences
Alternative Names: RLS-103Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator MannKind Corporation; Receptor Life Sciences
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Anxiety disorders; Epilepsy
Most Recent Events
- 02 Apr 2024 Receptor Life Sciences withdraws a phase I/II trial in Anxiety disorders in USA (Inhalation) due to lack of enrollment (NCT05429788)
- 02 Apr 2024 Receptor Life Sciences terminates phase I trials in Epilepsy in USA (Inhalation) (NCT05678881)
- 01 Nov 2022 Receptor Life Sciences has an open IND with the US FDA for a phase 1b trial in Epilepsy